A new boron compound (guanidine biboric acid adduct) as an antitumour agent against Ehrlich ascites carcinoma in mice.

Abstract

The inhibitory effects of a new boron compound of guanidine biboric acid adduct (GB) and guanidium chloride (L1) on the growth of ascites tumour in female Swiss mice were studied by monitoring the survival, tumour weight, tumour cell count, transplantability of Ehrlich ascites cells, precursor incorporation and the haematological parameters of the treated mice. 5-Fluorouracil, a known anticancer drug, was used as a positive control. The most important parameter was the survival time, which increased significantly when tumour-bearing mice were treated with the boron compound. Haematological parameters of the treated animals showed minimum toxic effects when boron was coupled with guanidine.

• Authors: P Ghosh, B Sur, S P Bag, P Sur
• Journal: Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine (Tumour Biol) 1999 Jan-Feb Vol. 20 Issue 1 Pg. 44-51 ISSN: 1010-4283 [Print] Netherlands
• PMID: 9858874 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antimetabolites, Antineoplastic
• Antineoplastic Agents
• Boric Acids
• Boron Compounds
• DNA, Neoplasm
• Guanidines
• guanidine biboric acid adduct
• Guanidine
• Fluorouracil

Topics

• Animals
• Antimetabolites, Antineoplastic (pharmacology)
• Antineoplastic Agents (pharmacology)
• Boric Acids (pharmacology)
• Boron Compounds
• Carcinoma, Ehrlich Tumor (blood, drug therapy, metabolism)
• Cell Division (drug effects)
• DNA, Neoplasm (biosynthesis)
• Female
• Fluorouracil (pharmacology)
• Guanidine (analogs & derivatives, pharmacology)
• Guanidines
• Lethal Dose 50
• Leukocyte Count (drug effects)
• Mice
• Neoplasm Transplantation